Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGuIX With Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma
NCT04881032Phase 2Active, not recruiting
- Sponsor
- Centre Jean Perrin
- Start
- Mar 2022
- Primary completion
- Nov 2026
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of AGuIX in glioblastoma (GBM), sponsored by Centre Jean Perrin. Started Mar 2022; status: active, not recruiting.
02
Drugs
AGuIX
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04881032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04881032.